Startup database

Pharma & Drug Discovery

Target discovery, molecule design and translational tooling, increasingly compute first.

52 companies

XtalPi

AI drug discovery

Combines quantum physics, artificial intelligence, and robotics for molecule discovery.

Public$786M raisedShenzhen, China

Insitro

AI drug discovery

Combines machine learning and high-throughput biology to transform drug discovery.

Series C+$743M raisedSouth San Francisco, USA

Recursion Pharmaceuticals

AI drug discovery

Combines automation and machine learning to industrialize drug discovery and development.

Public$665M raisedSalt Lake City, United States

Relay Therapeutics

Structure based design

Applies structural biology and computational chemistry to target protein motion.

Public$520M raisedCambridge, United States

Exscientia

AI drug discovery

Signal 100

Uses AI to design patient first precision medicines and optimize clinical trials.

Public$440M raisedOxford, United Kingdom

Valo Health

AI drug discovery

Signal 100

Integrates human data and machine learning to accelerate therapeutic discovery.

Series C+$439M raisedBoston, United States

Schrodinger

Computational chemistry

Signal 100

Provides physics based software solutions to accelerate molecular discovery and design.

Public$410M raisedNew York, United States

Insilico Medicine

AI drug discovery

Signal 100

Applies generative AI to discover new drug candidates and identify novel disease targets.

Series C+$401M raisedHong Kong, China

BenevolentAI

AI drug discovery

Employs an artificial intelligence platform to discover novel therapies for complex diseases.

Public$300M raisedLondon, United Kingdom

Genesis Therapeutics

AI drug discovery

Signal 100

Uses deep learning and molecular simulations to discover small molecule drugs.

Series B$280M raisedBurlingame, United States

AbCellera

Antibody discovery

Discovers and develops antibody therapeutics using high throughput microfluidics.

Public$245M raisedVancouver, Canada

Enveda Biosciences

Natural product discovery

Translates nature's chemistry into small-molecule therapeutics using AI and metabolomics.

Series C+$230M raisedBoulder, USA

Basecamp Research

AI-designed therapeutics

Frontier AI company designing medicines with EDEN, biological foundation models trained on a large proprietary evolutionary dataset.

Series C$225M raisedLondon, United Kingdom

Sling Therapeutics

Thyroid eye disease

Developing an oral small-molecule treatment for thyroid eye disease in a Phase 3 trial.

Series C$200M raisedAnn Arbor, United States

Terray Therapeutics

AI drug discovery

Signal 100

Combines ultra high throughput chemical synthesis with AI to find small molecules.

Series B$200M raisedPasadena, United States

Atomwise

AI drug discovery

Utilizes deep learning for structure based small molecule drug discovery.

Series B$174M raisedSan Francisco, United States

Plexium

Protein degradation

Discovers targeted monovalent protein degraders using high-throughput cellular screening.

Series C+$165M raisedSan Diego, USA

Iambic Therapeutics

AI drug discovery

Accelerates drug discovery through generative AI and high-throughput physics models.

Series B$152M raisedSan Diego, USA

Evozyne

Protein design

Uses advanced machine learning to design highly functional synthetic proteins.

Series B$139M raisedChicago, USA

Verge Genomics

AI drug discovery

Discovers therapeutics for neurodegenerative diseases utilizing human genomic data.

Series B$134M raisedSouth San Francisco, USA

Unlearn.AI

Clinical trial design

Creates digital twins of patients to run smaller and faster clinical trials.

Series C+$130M raisedSan Francisco, United States

Healx

Rare disease therapies

Uses artificial intelligence to discover and develop treatments for rare diseases.

Series B$103M raisedCambridge, UK

Estuary Biotherapeutics

Kidney gene therapy

Developing kidney-directed gene therapies.

Series A$103M raised

Causaly

Literature search and synthesis

Accelerates scientific research discovery through artificial intelligence driven literature synthesis.

Series B$93M raisedLondon, United Kingdom

Standigm

AI drug discovery

Employs deep learning workflows to streamline early-stage drug discovery projects.

Series C+$68M raisedSeoul, South Korea

RegCell

Cell therapy

Epigenetic reprogramming of auto-reactive T cells into antigen-specific regulatory T cells.

Series A$66M raisedEmeryville, CA

Profluent

Protein design

Generates custom proteins and gene-editing systems using deep learning models.

Series A$44M raisedBerkeley, USA

LabGenius

Protein design

Uses machine learning and robotic automation to discover novel protein therapeutics.

Series B$43M raisedLondon, UK

Peptone

Protein therapeutics

Designs therapeutic proteins using biophysics and advanced computational modeling.

Series A$40M raisedLondon, United Kingdom

Cradle

Protein design

Provides generative AI software for engineering proteins and optimizing cellular factories.

Series A$33M raisedDelft, Netherlands

PostEra

AI drug discovery

Uses machine learning to automate medicinal chemistry and speed up drug synthesis.

Series A$26M raisedBoston, USA

Altis Labs

Clinical trial endpoints

AI imaging endpoints designed to predict survival outcomes earlier in oncology clinical trials.

Series A$25M raisedToronto, Canada

VeriSIM Life

Translational prediction

Predicts clinical success of drug candidates using biosimulation and machine learning.

Series A$25M raisedSan Francisco, United States

A-Alpha Bio

Protein design

Measures and models protein-protein interactions at scale using synthetic biology.

Series A$22M raisedSeattle, USA

Pharos iBio

AI drug discovery

Uses deep learning to discover treatments for rare and orphan diseases.

Public$20M raisedAnyang, South Korea

HexemBio

Synthetic biology

Synthetic yolk sac platform that rejuvenates aged blood stem cells for transplant.

Seed$16M raisedSan Francisco, CA

Iktos

AI drug discovery

Develops generative AI models for automated de novo drug design.

Series A$16M raisedParis, France

Graph AI

Pharmacovigilance AI

AI platform automating drug safety and pharmacovigilance workflows for life sciences companies.

Series A$13M raisedPleasanton, United States

Biorelate

Biomedical data curation

Extracts dark biomedical data from text to aid drug discovery.

Series A$11M raisedManchester, UK

InSilicoTrials

Clinical trial simulation

Provides computational modeling and simulation software for virtual drug trials.

Series A$10M raisedTrieste, Italy

Outer Bio

Human skin models and AI discovery

A discovery platform combining long-lived ex vivo human skin models with machine learning.

SeedUndisclosed

Prime Medicine

Prime editing

Prime editing company developing genetic therapies for inherited diseases.

PublicUndisclosedCambridge, MA, USA

Ultragenyx Pharmaceutical

Rare disease gene therapy

Rare-disease biotechnology company behind the first FDA-approved gene therapy for pediatric MPS IIIA.

PublicUndisclosedNovato, CA, USA

Coefficient Bio

Generative biology

AI drug discovery company acquired by Anthropic and integrated into its life sciences team.

GrowthUndisclosedNew York, NY, USA

Anthropic

Frontier AI

Frontier AI company expanding Claude into scientific research and life sciences workflows.

GrowthUndisclosedSan Francisco, CA, USA

Eli Lilly and Company

Targeted oncology

Global drugmaker behind Inluriyo, the oral SERD approved with Verzenio for ESR1 mutated breast cancer.

PublicUndisclosedIndianapolis, United States

Egetis Therapeutics

Rare disease endocrinology

Rare disease drug developer behind Emcitate (tiratricol) for MCT8 deficiency.

PublicUndisclosedStockholm, Sweden

Bayer

Cardiorenal medicines

Global life sciences company developing medicines across cardiology, nephrology, oncology and women's health.

PublicUndisclosedLeverkusen, Germany

IntraBio

Rare neurology

Rare disease company behind Aqneursa, approved for ataxia in ataxia telangiectasia.

GrowthUndisclosedAustin, United States

Scholar Rock

Neuromuscular and rare diseases

A biopharmaceutical company developing medicines that target growth factors in their local tissue environments.

PublicUndisclosedCambridge, USA

Panacea

AI-native FDA regulatory services

AI-native regulatory services for biotechnology and medical device companies.

Pre-seedUndisclosedSan Francisco, USA

Isomorphic Labs

AI drug discovery

Uses artificial intelligence and biological modeling to accelerate drug design.

GrowthUndisclosedLondon, UK